Medisca Launches Global Peptide Division
This new division brings API-grade peptides and Medisca’s quality-focused pharmaceutical expertise to the rapidly growing field of personalised medicine.
Montreal—Medisca today announced the launch of Medisca Peptides, a dedicated global division focused on expanding access to API-grade (Active Pharmaceutical Ingredient) peptides and developing an integrated peptide platform for the global pharmaceutical and personalised medicine markets. As the field of peptides evolves, Medisca is proactively building the necessary capabilities and infrastructure to support API-grade peptides within applicable regulatory frameworks.
The launch marks a significant long-term commitment to peptides, including the expansion of Medisca’s portfolio, strategic manufacturing partnerships, and the pharmaceutical infrastructure required to support the growth of this category. The launch also signals Medisca’s ambition to become a leading force in next-generation peptide innovation.
For Medisca, this opportunity is not new. More than 35 years ago, the company was founded to help bridge the gap between the pharmaceutical standards required by formulators and the high-quality raw materials they could easily obtain. Today, as peptides emerge as a critical field in pharmaceutical innovation and personalised medicine, Medisca sees another pivotal moment for the industry; a moment where quality, regulatory responsibility, and responsible access will become crucial factors for the future of the category.
The category is expanding, and Medisca plans to help set its standards.
“When I founded Medisca, I saw an opportunity to bring pharmaceutical compounding practices closer to conventional pharmaceutical industry standards by providing better access to API-grade raw materials and applying higher standards to those materials,” said Antonio Dos Santos, Founder and Chief Executive Officer of Medisca. “Today, I see a similar opportunity in the field of peptides. We are entering this field not merely to follow a trend, but with the intention to help shape it.”
Establishing higher standards for peptide quality
Medisca’s approach begins at the source. The company has selected leading manufacturing partners who share the same philosophy of prioritising quality, focusing on pharmaceutical experience, proven quality systems, manufacturing expertise, and robust quality and compliance practices.
Medisca will implement established processes regarding manufacturer qualification, product testing, documentation, and supply chain oversight for the peptide APIs it markets. This control is vital for peptides, where production complexity, characterisation, purity, and contaminants associated with peptides present unique quality considerations. Medisca is committed to operating within applicable regulatory frameworks and supporting responsible access to peptide APIs.
Building an Integrated Peptide Platform
Medisca Peptides focuses not only on API supply but also integrates expertise in formulation, blending technology and equipment, analytical services, education, and technical support.
By connecting these various capabilities into a single platform, Medisca aims to support healthcare professionals and pharmaceutical partners with the raw materials and expertise required to navigate the evolving peptide landscape.
“Healthcare professionals and pharmaceutical partners need more than just confidence in the quality and origin of peptide APIs; they also require the expertise and infrastructure to translate that innovation into practice,” said Charlie Guerini, Chief Commercial Officer at Medisca. “That is what we are developing with Medisca Peptides: an integrated platform that combines an expanding API portfolio, carefully selected manufacturing partners, reliable supply, and the technical expertise our customers have trusted for decades.”
Shaping the Future of Peptide Innovation
This launch marks the beginning of a broader, long-term strategy to position Medisca as a global leader in peptide quality, supply, and innovation.
Medisca will expand its peptide API portfolio and strategic manufacturing partnerships, while investing in the scientific, analytical, formulation, technical, and educational capabilities necessary to develop opportunities in the pharmaceutical and personalised medicine sectors.
Beyond supply, Medisca will take an active leadership role in shaping the future of peptides by advocating for the implementation of additional safety guidelines, transparency, responsible access, and appropriate quality standards, while working alongside manufacturers, healthcare professionals, and industry stakeholders as science, regulation, and clinical practice evolve.
The goal is clear: to help shape the next generation of peptides by combining the quality, expertise, and integrated solutions required to advance the category.
Medisca Peptides will begin its rollout in selected global markets, with further announcements regarding additional portfolio expansions, strategic partnerships, and company capabilities to follow.